Huons Global said Tuesday the company and its subsidiaries recorded 100.3 billion won ($88.1 million) in sales in the third quarter of this year, up 16.8 percent from the same period of 2017.

This is the first time that the company has surpasses 100 billion won in sales in a single quarter. The company also registered 20.9 billion won in operating profit in the same period, a 13.9 percent increase from a year ago, while recording 21.4 billion won in net profit, up 42.8 percent.

Aside from its subsidiaries, Huons Global alone posted 7.4 billion won in sales, 2.8 billion in operating profit and 3.1 billion won in net profit. “Huons Global's record-high earnings in the second quarter were driven by sales growth from its subsidiaries such as Huons, Hubena and Huons Medicare,” the company said.

Huons said it believes the growth momentum will continue as its subsidiaries are continuing to grow, while the local phase 3 clinical trial for Hutox, its botulinum toxin (BTX), on forehead wrinkle improvement has ended successfully, it added.

Huons plans to launch Hutox in Korea in the second half of next year. After the launch, the company will systematically promote global clinical and overseas licenses based on large-scale, long-term export contracts with countries such as Europe, Brazil and Russia.

To match global demands in advance, Huons Global is building a second factory, which is five times more productive than its first plant, ensuring a stable supply of its BTX. The company expects to complete the construction of the factory and receive good manufacture practice (GMP) from the Ministry of Food and Drug Safety in the second half year. Once completed, the first and second factories will be able to produce about six million vials annually.

Huons Global plans to conduct phase 1 and phase 3 clinical trials for 'improvement of external angle wrinkles (eye wrinkles)' and aim to acquire indication by 2020.

“As Hutox's domestic clinical trials have been completed and domestic launches will start in earnest next year, we believe it will serve as a strong growth momentum,” Huons Global Vice Chairman Yoon Sung-tae said. “Since Huons, Humedix, and other subsidiaries are maintaining solid sales increase, and the company expects its growth to continue.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>